Boswellia (Indian Frankincense) is a powerful anti-inflammatory resin extract containing boswellic acids that selectively inhibit 5-lipoxygenase enzyme, reducing inflammatory leukotrienes without the side effects of NSAIDs, with strong clinical evidence for osteoarthritis, asthma, and inflammatory bowel conditions, and enhanced absorption forms like AprèsFlex and Casperome offering superior bioavailability.
Alternative Names: Boswellia serrata, Indian frankincense, Salai guggul, Shallaki, Olibanum indicum, Boswellin
Categories: Anti-inflammatory, Herbal Extract, Ayurvedic Herb, Resin Extract
Primary Longevity Benefits
- Anti-inflammatory effects
- Joint health support
- Cellular protection
- Pain reduction
Secondary Benefits
- Respiratory health
- Digestive health
- Cognitive function
- Skin health
- Immune modulation
- Vascular health
- Neuroprotection
- Cancer adjunctive support
Mechanism of Action
Boswellia exerts its diverse biological effects primarily through the actions of boswellic acids, a group of pentacyclic triterpene compounds found in the resin. The most potent and well-studied of these is 3-O-acetyl-11-keto-β-boswellic acid (AKBA), though other boswellic acids also contribute to the overall effects. The primary anti-inflammatory mechanism of boswellic acids involves selective inhibition of 5-lipoxygenase (5-LOX), a key enzyme in the biosynthesis of leukotrienes from arachidonic acid. By binding directly to 5-LOX, AKBA and other boswellic acids reduce the production of pro-inflammatory leukotrienes, particularly leukotriene B4, which are potent mediators of inflammation involved in various inflammatory conditions including arthritis, asthma, and inflammatory bowel disease.
This mechanism differs from conventional non-steroidal anti-inflammatory drugs (NSAIDs), which primarily inhibit cyclooxygenase (COX) enzymes, giving boswellia a unique therapeutic profile with potentially fewer side effects on the gastrointestinal and cardiovascular systems. Beyond 5-LOX inhibition, boswellic acids modulate multiple inflammatory pathways: they inhibit the NF-κB signaling pathway, reducing the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6; decrease the activity of human leukocyte elastase (HLE), an enzyme involved in tissue damage during inflammation; and reduce the expression of matrix metalloproteinases (MMPs) that degrade extracellular matrix components in inflammatory conditions. In joint tissues, boswellic acids help preserve cartilage integrity by inhibiting glycosaminoglycan degradation and reducing the production of pro-inflammatory mediators by chondrocytes and synoviocytes. They also modulate immune cell function, reducing neutrophil infiltration into inflamed tissues and modifying T-cell signaling to favor anti-inflammatory responses.
For respiratory health, boswellia compounds reduce bronchial inflammation through leukotriene inhibition and decrease mucus hypersecretion, potentially benefiting conditions like asthma and chronic bronchitis. In the digestive system, boswellic acids reduce intestinal inflammation and help maintain mucosal integrity, supporting their traditional use for inflammatory bowel conditions. Boswellia’s effects on cognitive function may stem from its anti-inflammatory actions in neural tissues, reduction of oxidative stress, and potential neuroprotective properties. Some research suggests boswellic acids may inhibit acetylcholinesterase, potentially enhancing cholinergic neurotransmission relevant to cognitive function.
In cancer research, boswellic acids have demonstrated potential anticancer properties through multiple mechanisms: induction of apoptosis in various cancer cell lines; inhibition of topoisomerases, enzymes involved in DNA replication; disruption of angiogenesis through VEGF pathway modulation; and reduction of tumor-promoting inflammation. Additionally, boswellic acids possess moderate antioxidant properties, though this is not their primary mechanism of action. They may also influence microbiome composition, potentially contributing to their anti-inflammatory effects through gut-immune system interactions.
Optimal Dosage
Disclaimer: The following dosage information is for educational purposes only. Always consult with a healthcare provider before starting any supplement regimen, especially if you have pre-existing health conditions, are pregnant or nursing, or are taking medications.
300-1200 mg per day of standardized extract (containing 30-65% boswellic acids), typically divided into 2-3 doses. Dosage varies based on the specific condition being addressed, the standardization level of the extract, and the specific formulation used.
By Condition
| Condition | Dosage | Notes |
|---|---|---|
| Osteoarthritis | 100-250 mg of AKBA-enriched extracts (5-Loxin®, AprèsFlex®) daily, or 300-1000 mg of standard boswellia extract (30-65% boswellic acids) daily | Clinical studies show significant improvement in joint pain and function at these doses after 4-8 weeks of consistent use. Enhanced formulations like AprèsFlex may be effective at lower doses. |
| Rheumatoid arthritis | 600-1200 mg of standard extract daily, divided into 3 doses | May take 2-4 weeks for significant benefits. Often combined with other anti-inflammatory herbs or conventional treatments. |
| Inflammatory bowel disease (Crohn’s, ulcerative colitis) | 800-1200 mg of standard extract daily, divided into 3 doses | Clinical studies have shown benefits at these doses for maintaining remission and reducing symptoms. |
| Asthma | 300-400 mg of standard extract three times daily (900-1200 mg total) | Studies show reduced frequency of attacks and improved breathing parameters after 6-8 weeks. |
| General inflammation | 300-500 mg of standard extract daily | Lower preventive doses are often effective for general anti-inflammatory support in otherwise healthy individuals. |
| Brain inflammation/cognitive support | 500-1000 mg of standard extract daily | Emerging research area with limited clinical evidence, but mechanistic studies support potential benefits. |
| Topical application (creams, ointments) | As directed by product (typically containing 2-5% boswellia extract) | Apply to affected areas 2-3 times daily for localized inflammation and pain. |
By Age Group
| Age Group | Dosage | Notes |
|---|---|---|
| Children | Not established | Limited research in pediatric populations. Use only under healthcare provider supervision with age-appropriate dosing. |
| Adolescents (13-17 years) | Approximately half the adult dose | Limited research in this age group. Use with caution and medical supervision. |
| Adults (18-64 years) | 300-1200 mg of standard extract daily | Dose depends on specific condition being addressed and individual response. |
| Older adults (65+ years) | 300-1000 mg of standard extract daily | Start at lower doses and increase gradually. May be particularly beneficial for inflammatory conditions common in this age group. |
Bioavailability
Absorption Rate
Boswellic acids have relatively poor oral bioavailability, with standard extracts showing absorption rates of approximately 1-3% of the ingested dose. This limited bioavailability is primarily due to their lipophilic nature and poor water solubility. After oral administration, boswellic acids are absorbed in the gastrointestinal tract, with peak plasma concentrations typically reached within 4-5 hours. The most pharmacologically active component, AKBA (3-O-acetyl-11-keto-β-boswellic acid), shows particularly poor bioavailability compared to other boswellic acids.
Despite this limited systemic absorption, clinical efficacy has been demonstrated, suggesting that even low plasma concentrations may be sufficient for therapeutic effects or that local effects in the gastrointestinal tract may contribute to overall benefits.
Enhancement Methods
Taking with a high-fat meal can increase absorption by 2-3 fold due to enhanced solubilization, Phospholipid complexes (phytosomes) can increase bioavailability by 3-5 fold, Liposomal formulations improve cellular uptake and systemic distribution, Nano-emulsions and nano-particles significantly enhance absorption by increasing surface area, Proprietary formulations like AprèsFlex/Aflapin have demonstrated up to 52% greater bioavailability of AKBA, Casperome® (lecithin-based delivery system) shows improved plasma levels of boswellic acids, Combining with piperine (black pepper extract) may enhance absorption through inhibition of intestinal metabolism, Solid lipid nanoparticles improve stability and absorption, Micronization techniques increase surface area for better dissolution
Timing Recommendations
Boswellia extract is best taken with meals, particularly those containing some fat, to enhance absorption of the lipophilic boswellic acids. For inflammatory conditions, dividing the daily dose into 2-3 administrations throughout the day provides more consistent blood levels than a single daily dose. For joint conditions, some practitioners recommend taking the last dose of the day in the evening to help manage morning stiffness, though this is based on clinical experience rather than formal studies. For digestive conditions like inflammatory bowel disease, taking doses with meals may provide direct local effects on the gastrointestinal tract in addition to systemic effects.
For respiratory conditions, consistent timing throughout the day helps maintain anti-inflammatory effects in bronchial tissues. For general anti-inflammatory benefits, consistent daily dosing is more important than specific timing. When using enhanced bioavailability formulations (phytosomes, AprèsFlex, etc.), follow manufacturer recommendations, as these may have different optimal timing based on their specific delivery mechanisms.
Safety Profile
Safety Rating
Side Effects
- Mild gastrointestinal discomfort (nausea, acid reflux, diarrhea)
- Allergic skin reactions (rare)
- Headache (uncommon)
- Dizziness (rare)
- Nausea (uncommon)
- Mild abdominal pain (uncommon)
- Temporary skin rash (rare)
- Heartburn (particularly with higher doses)
Contraindications
- Known allergy to Boswellia or other plants in the Burseraceae family
- Pregnancy (insufficient safety data, though traditional use suggests safety)
- Breastfeeding (insufficient safety data)
- Scheduled surgery within 2 weeks (due to potential anticoagulant effects)
- Severe liver disease (use with caution as metabolism may be affected)
- Severe kidney disease (limited safety data in these populations)
- Active gastric or duodenal ulcers (may potentially exacerbate in some individuals)
Drug Interactions
- Anticoagulant/antiplatelet medications (theoretical potential for additive effects, though clinical significance appears minimal at standard doses)
- Immunosuppressant drugs (potential interference due to immunomodulatory effects)
- Anti-inflammatory medications (potential additive effects, generally beneficial but may require monitoring)
- Medications metabolized by cytochrome P450 enzymes (theoretical interaction, limited clinical evidence)
- Diabetes medications (may enhance blood sugar-lowering effects in some individuals)
- Lipid-lowering medications (potential additive effects on cholesterol levels)
Upper Limit
No official upper limit has been established. Clinical studies have used doses up to 1200 mg of standard extract daily without significant adverse effects in most participants. For enhanced formulations like AprèsFlex or 5-Loxin, the upper tested doses are typically 100-250 mg daily. Long-term safety studies (beyond 1 year) are limited, though traditional use suggests safety with extended use. As with any supplement, it’s prudent to use the lowest effective dose for the intended purpose.
Regulatory Status
Fda Status
In the United States, boswellia extract is regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994.
It has not been approved as a drug for any specific indication. As a supplement, manufacturers cannot make claims about treating, curing, or preventing specific diseases, but can make structure/function claims about supporting normal bodily functions (e.g., ‘supports joint health’). The FDA has not issued any specific warnings or restrictions regarding boswellia supplements.
International Status
Eu: In the European Union, boswellia is recognized as a traditional herbal medicinal product under Directive 2004/24/EC for specific indications including joint and musculoskeletal pain, minor inflammatory conditions, and digestive disorders. The European Medicines Agency (EMA) has published a community herbal monograph for Indian frankincense (Boswellia serrata), recognizing its traditional medicinal use. In some EU countries, boswellia products may be registered as traditional herbal medicinal products, while in others they may be marketed as food supplements.
Germany: The German Commission E (similar to the FDA for herbal medicines) has approved boswellia for chronic inflammatory diseases, particularly rheumatoid arthritis, bronchial asthma, and inflammatory bowel diseases. Several boswellia products are registered as traditional herbal medicinal products in Germany.
India: In India, boswellia (Shallaki) is recognized in the Ayurvedic Pharmacopoeia of India and is regulated as an Ayurvedic medicine by the Ministry of AYUSH. It is approved for various inflammatory conditions, particularly arthritis. Several standardized boswellia extracts are licensed as prescription and over-the-counter medications in India.
Australia: The Therapeutic Goods Administration (TGA) regulates boswellia as a listed complementary medicine ingredient. Several boswellia products are included in the Australian Register of Therapeutic Goods (ARTG) with permitted indications related to anti-inflammatory effects and joint health.
Canada: Health Canada regulates boswellia as a Natural Health Product (NHP) ingredient. Several boswellia products have received Natural Product Numbers (NPNs) with approved claims related to joint health, anti-inflammatory effects, and digestive health.
China: Boswellia (Ru Xiang) is included in the Chinese Pharmacopoeia and is regulated as a traditional Chinese medicine ingredient by the National Medical Products Administration (NMPA).
Japan: Boswellia is regulated as a non-pharmaceutical ingredient and can be used in foods with functional claims under Japan’s Foods with Function Claims (FFC) system, though specific product approvals are required.
Synergistic Compounds
| Compound | Synergy Mechanism | Evidence Rating |
|---|---|---|
| Curcumin | Curcumin inhibits inflammatory pathways complementary to boswellia’s 5-LOX inhibition, particularly NF-κB and COX-2. While boswellia primarily reduces leukotriene production, curcumin more strongly affects prostaglandin synthesis. Together, they provide more comprehensive anti-inflammatory effects targeting multiple inflammatory mediators. | 4 |
| Glucosamine and Chondroitin | These compounds provide building blocks for cartilage repair and maintenance, while boswellia reduces the inflammatory processes that contribute to cartilage degradation. This combination addresses both structural support and inflammatory aspects of joint health. | 3 |
| MSM (Methylsulfonylmethane) | MSM provides sulfur for joint tissue repair and has mild anti-inflammatory properties. Combined with boswellia’s stronger anti-inflammatory effects, this synergy supports both inflammation reduction and structural joint health. | 2 |
| Ginger | Ginger inhibits both COX-2 and 5-LOX pathways, but through different mechanisms than boswellia. It also has anti-nausea properties that may help counteract any mild digestive discomfort from boswellia. Together they provide enhanced anti-inflammatory effects. | 3 |
| Omega-3 Fatty Acids | Omega-3s compete with arachidonic acid in inflammatory pathways, reducing substrate availability for both 5-LOX and COX enzymes. This complements boswellia’s direct enzyme inhibition, providing multi-level modulation of inflammatory processes. | 3 |
| Piperine (Black Pepper Extract) | Piperine may enhance the bioavailability of boswellic acids by inhibiting intestinal and hepatic metabolism. It also has mild anti-inflammatory properties that may complement boswellia’s effects. | 2 |
| Frankincense Essential Oil (from same Boswellia species) | The essential oil contains different terpenes and volatile compounds that complement the boswellic acids in the resin extract. When used topically together, they may provide enhanced local anti-inflammatory effects. | 2 |
| Ashwagandha | Ashwagandha’s adaptogenic and anti-stress properties complement boswellia’s anti-inflammatory effects. Chronic stress can exacerbate inflammation, so this combination addresses both inflammatory processes and one of their triggers. | 2 |
| Bromelain | Bromelain’s proteolytic activity helps break down inflammatory proteins and may enhance tissue penetration of boswellic acids. Both have anti-inflammatory effects through different mechanisms. | 2 |
| Vitamin D | Vitamin D modulates immune function and has anti-inflammatory properties that complement boswellia’s effects. It’s particularly relevant for joint health, where vitamin D deficiency is associated with increased inflammation. | 2 |
Antagonistic Compounds
| Compound | Interaction Type | Evidence Rating |
|---|---|---|
| Anticoagulant medications (Warfarin, Heparin, etc.) | Theoretical concern that boswellia might enhance the effects of anticoagulant medications due to potential mild antiplatelet effects. However, clinical significance appears minimal at standard doses, and no case reports of adverse interactions have been published. | 1 |
| Antiplatelet medications (Aspirin, Clopidogrel, etc.) | Theoretical concern that boswellia might enhance the effects of antiplatelet medications. However, clinical significance appears minimal at standard doses, and no case reports of adverse interactions have been published. | 1 |
| Immunosuppressant medications | Boswellia’s immunomodulatory effects might theoretically interfere with immunosuppressant medications, though clinical evidence of significant interaction is limited. | 1 |
| Medications metabolized by cytochrome P450 enzymes | Some in vitro studies suggest boswellic acids may affect certain cytochrome P450 enzymes, potentially altering the metabolism of drugs dependent on these pathways, though clinical significance appears minimal at typical doses. | 1 |
| Antacids | May potentially reduce absorption of boswellic acids if taken simultaneously. Separating doses by 2 hours may minimize this potential interaction. | 1 |
| Proton Pump Inhibitors | Theoretical concern that reduced stomach acid might affect the dissolution and absorption of boswellic acids, though clinical significance is unclear. | 1 |
| Diabetes medications | Boswellia may enhance blood glucose-lowering effects in some individuals, potentially requiring monitoring and dosage adjustments of diabetes medications. | 2 |
| Alcohol | No direct antagonistic interaction, but alcohol may increase gastrointestinal irritation when combined with boswellia, potentially exacerbating mild digestive side effects. | 1 |
| Leukotriene synthesis promoters | Compounds that increase leukotriene production would theoretically counteract boswellia’s 5-LOX inhibition, though specific examples of this interaction are not well-documented. | 1 |
| Calcium supplements | Theoretical interaction where calcium might bind to boswellic acids, potentially reducing absorption. Clinical significance is likely minimal, but separating doses by 2 hours may be prudent. | 1 |
Cost Efficiency
Relative Cost
Low to Medium
Cost Per Effective Dose
Standard extract (300-1000 mg daily with 30-65% boswellic acids): $0.30-$0.80 per day. Enhanced bioavailability formulations (AprèsFlex/Aflapin, 5-Loxin, Casperome): $0.80-$2.00 per day. Premium standardized extracts with higher AKBA content: $0.60-$1.50 per day. Combination formulas with other anti-inflammatory compounds: $1.00-$2.50 per day.
Value Analysis
Boswellia extract offers excellent cost efficiency compared to many anti-inflammatory supplements and medications. When comparing boswellia products, cost per milligram of boswellic acids (particularly AKBA) provides the most accurate value comparison, as potency varies significantly between products. Products standardized only by weight without specifying boswellic acid content may contain minimal active compounds and represent poor value regardless of price. Enhanced bioavailability formulations (AprèsFlex/Aflapin, 5-Loxin, Casperome) typically cost 2-3 times more than standard extracts but may provide better results at lower doses, potentially offering comparable or better value despite the higher price.
For joint health, boswellia compares favorably to glucosamine/chondroitin supplements in terms of both cost and efficacy, with more rapid onset of action in most studies. Compared to NSAIDs and other anti-inflammatory medications, boswellia offers significant cost savings for long-term use and typically has fewer side effects, though may not be as potent for acute inflammation. Generic and store-brand boswellia products have become more available in recent years, offering 20-30% cost savings over premium brands, though quality can be variable. Bulk purchases and subscription services typically offer 10-20% savings over one-time purchases.
For general anti-inflammatory support, lower doses (300-500 mg of standard extract) provide good value, while higher doses for therapeutic effects naturally increase costs. Combination products with synergistic compounds like turmeric/curcumin may provide better overall value for comprehensive anti-inflammatory support than boswellia alone, despite higher upfront costs. The relatively long shelf life (2-3 years) allows for bulk purchasing without significant waste risk. For those primarily seeking 5-LOX inhibition, specialized high-AKBA extracts may offer better value than higher doses of standard extracts, despite the premium price.
Stability Information
Shelf Life
Properly manufactured and stored boswellia extract supplements typically maintain acceptable boswellic acid content for 2-3 years. Capsules and tablets generally have longer stability than powder forms due to reduced exposure to environmental factors. Raw resin has an exceptionally long shelf life, with archaeological samples thousands of years old still containing identifiable boswellic acids, though potency gradually decreases over time.
Storage Recommendations
Store in a cool, dry place away from direct sunlight. Optimal temperature range is 15-25°C (59-77°F). Refrigeration is not necessary for most formulations and may actually introduce moisture through condensation when the container is opened. Keep containers tightly closed to prevent moisture absorption, as moisture can accelerate degradation of boswellic acids.
The original container typically provides appropriate protection from light and moisture. Avoid storing in bathrooms or kitchens where temperature and humidity fluctuate. For powder forms, use a dry measuring tool to prevent introducing moisture. Once opened, use within the timeframe recommended by the manufacturer (typically 1-2 years) for optimal boswellic acid content.
Raw resin should be stored in airtight containers, preferably made of glass or ceramic, to preserve its aromatic compounds and prevent oxidation.
Degradation Factors
Heat accelerates oxidation of boswellic acids, Light exposure, particularly UV light, can cause photodegradation, Oxygen exposure leads to oxidation of terpene compounds, Moisture causes hydrolysis of acetyl groups on boswellic acids (particularly AKBA), Microbial contamination if exposed to moisture, Enzymatic degradation if exposed to certain enzymes, Extreme pH conditions can accelerate degradation, Metal ions, particularly iron and copper, can catalyze oxidation, Repeated freeze-thaw cycles may affect stability of some formulations, Time gradually reduces potency even under optimal storage conditions
Sourcing
Synthesis Methods
- Extraction from tree resin (primary commercial method)
- Traditional collection of resin tears from incisions in the tree bark
- Solvent extraction (typically ethanol or methanol)
- Supercritical CO2 extraction for higher purity
- Concentration through vacuum evaporation
- Standardization to specific boswellic acid content (typically 30-65%)
- AKBA enrichment processes for premium extracts
- Phospholipid complexation for enhanced bioavailability formulations
- Nano-emulsification for improved absorption
- Quality control through HPLC analysis of boswellic acid content
Natural Sources
- Boswellia serrata (Indian frankincense) – primary commercial source
- Boswellia carterii (Somali frankincense)
- Boswellia sacra (Arabian frankincense)
- Boswellia frereana (African frankincense)
- Boswellia papyrifera (Ethiopian frankincense)
- Note: Different Boswellia species have varying boswellic acid profiles and potencies
Quality Considerations
Standardization is critical – look for products standardized to total boswellic acid content (typically 30-65%) and/or AKBA content (typically 5-30%). Species matters significantly – Boswellia serrata is the most studied species with the most consistent boswellic acid profile. Sustainable harvesting practices are important – over-tapping trees can lead to reduced resin quality and environmental damage. Extraction method affects compound profile – supercritical CO2 extraction generally produces higher quality extracts than solvent extraction. Enhanced bioavailability formulations (AprèsFlex/Aflapin, Casperome, etc.) may provide better results at lower doses than standard extracts. Avoid products containing fillers, artificial colors, or excessive excipients. Third-party testing verification provides additional assurance of potency and purity. Some premium products specify the complete boswellic acid profile (KBA, AKBA, β-boswellic acid, etc.), which can affect specific bioactivities. Country of origin matters – Indian Boswellia serrata is traditionally considered the standard for medicinal use. Resin color and aroma can indicate quality – premium resin should have a clear amber color and characteristic woody, spicy aroma. For traditional resin use, tears should be translucent with minimal bark contamination.
Historical Usage
Boswellia has one of the longest documented histories of human use among medicinal plants, spanning at least 5,000 years across multiple civilizations. The aromatic resin, commonly known as frankincense or olibanum, has been harvested from Boswellia trees native to regions spanning from East Africa to India. Ancient Egyptians used boswellia resin extensively in religious ceremonies, mummification processes, and medicinal preparations. Hieroglyphics dating back to 1500 BCE depict expeditions to obtain frankincense, which they called ‘antyw.’ Egyptian medical papyri mention frankincense for treating wounds, infections, and as a fumigant to ward off disease.
In ancient Mesopotamia, boswellia resin was highly valued for religious rituals and medicinal applications. Cuneiform tablets from Babylonian and Assyrian civilizations (circa 2000 BCE) describe frankincense for treating various ailments including inflammation, pain, and respiratory conditions. The resin achieved perhaps its most famous historical mention in the biblical account of the gifts brought to the infant Jesus by the Magi—gold, frankincense, and myrrh—highlighting its tremendous value in the ancient world. In traditional Ayurvedic medicine of India, Boswellia serrata (known as ‘Shallaki’ or ‘Salai guggul’) has been used for over 3,000 years.
Ayurvedic texts describe its use for arthritis, inflammation, respiratory conditions, digestive disorders, and skin diseases. The ancient Ayurvedic text Sushruta Samhita (circa 600 BCE) specifically mentions boswellia for treating arthritis and inflammation. Traditional Chinese Medicine incorporated frankincense (called ‘Ru Xiang’) around 500 CE, using it primarily for blood stagnation, pain relief, and inflammatory conditions. Greek and Roman physicians, including Hippocrates and Dioscorides, documented frankincense’s medicinal properties for treating wounds, inflammation, and gynecological conditions.
During the Middle Ages, Arabian physicians further developed medicinal applications for boswellia, with Avicenna’s Canon of Medicine describing its use for numerous conditions. Traditional African medicine systems in Ethiopia, Somalia, and other regions where Boswellia species grow naturally have long used the resin for pain, inflammation, infections, and spiritual practices. The frankincense trade was one of the world’s oldest and most important global commerce networks, with camel caravans transporting the precious resin along the ‘Incense Route’ from southern Arabia to Mediterranean ports. Modern scientific interest in boswellia began in the 1970s, with Indian researchers investigating the anti-inflammatory properties of Boswellia serrata extracts.
The identification of boswellic acids as the primary active compounds and the elucidation of their 5-lipoxygenase inhibition mechanism in the 1980s and 1990s sparked increased research interest. Today, standardized boswellia extracts are used in evidence-based complementary medicine worldwide, representing a remarkable continuity of medicinal use spanning millennia and bridging ancient traditional knowledge with modern scientific understanding.
Scientific Evidence
Evidence Rating
Key Studies
Meta Analyses
Yu G, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2020;20(1):225., Abdel-Tawab M, et al. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clinical Pharmacokinetics. 2011;50(6):349-369., Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database of Systematic Reviews. 2014;(5):CD002947.
Ongoing Trials
Boswellia Serrata for Knee Osteoarthritis (NCT04635774), Boswellia and Curcumin for Inflammatory Bowel Disease (NCT03607095), Boswellia Extract for Asthma Management (NCT04188184), Boswellia and Ashwagandha for Stress and Inflammation (NCT04684836), Topical Boswellia for Psoriasis (NCT04440540)
Disclaimer: The information provided is for educational purposes only and is not intended as medical advice. Always consult with a healthcare professional before starting any supplement regimen, especially if you have pre-existing health conditions or are taking medications.